Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
Complete Title: An Open-label,multicenter,Phase 1/2 study of RP1 as a single agent and in combination with PD1 blockade in patients with solid tumors.
Trial Phase: II
Investigator: Evan Hall
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
Keywords:
- Melanoma
- Skin Cancer
- Lung Carcinoma, Non-Small-Cell (NSCLC)
- Lymphoma, T-Cell, Cutaneous
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
II
Evan Hall
RG1123074
NCT03767348
An Open-label,multicenter,Phase 1/2 study of RP1 as a single agent and in combination with PD1 blockade in patients with solid tumors.
Melanoma
Skin Cancer
Lung Carcinoma, Non-Small-Cell (NSCLC)
Lymphoma, T-Cell, Cutaneous